Kamada, Chiesi Farmaceutici Terminate Inhaled Alpha-1 Antitrypsin Therapy Deal Post author:Sam Post published:November 19, 2017 Post category:BioPharma Kamada now maintains full, worldwide commercial rights to its inhaled AAT. Source: BioSpace You Might Also Like Avita Medical Taps Investors for A$16.9 Million to Commercialise Its 'Spray-On Skin' October 10, 2017 Pfizer Eyes $100 Million Expansion, New Jobs in North Carolina March 7, 2017 <b>UBM Medica</b>'s <b>Oncology And Society For Integrative Oncology (Sio)</b> Announce Partnership July 30, 2017
Avita Medical Taps Investors for A$16.9 Million to Commercialise Its 'Spray-On Skin' October 10, 2017
<b>UBM Medica</b>'s <b>Oncology And Society For Integrative Oncology (Sio)</b> Announce Partnership July 30, 2017
